Compare Emerson Electric Co. (EMR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Viatris Inc — how do they compare? Emerson Electric Co. trades at $161.83 (market cap $88.72B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Emerson Electric Co. is far larger — about 4.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Viatris Inc for 57 Days on average.
| EMR | VTRS | |
|---|---|---|
Market Cap | $88.72B | $20.03B |
Volume | 2,355,255 | 14,109,977 |
Sector | Industrials | Health |
52-Week High | $164.38 | $18.27 |
52-Week Low | $123.30 | $9.74 |
Typical Hold Time | 81 Days | 57 Days |
Enterprise Value | $99.80B | $32.15B |
Dividend Yield | 1.4% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $159.06, down slightly by 0.1% today, with a bullish technical signal from moving averages and a consensus price target of $165.90. The company has beaten earnings estimates for the last three quarters, with Q3 2026 EPS expected at $1.84. Revenue grew to $18.02B in 2025, and net income margin improved to 13.83%, supported by strong cash flow from operations of $3.10B.
EMR presents a favorable outlook with analyst buy ratings at 53.49% and projected revenue growth to $18.6B in 2026. Risks include elevated valuation ratios like a P/E of 34.81 and debt-to-asset ratio increase to 31.26 in 2025. The stock's upside is tied to continued earnings beats and operational execution amid industrial sector competition.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
